home.aspx
 
EVENTS

BIOFIT 2019
BIOFIT 2019
December 10-11, 2019
With the highest attending rate of academics, TTOs and research institutions, BioFIT is the place where academia-industry collaborations get started. BioFIT has taken on a whole new dimension becoming the meeting point in Europe for tech transfer and for sourcing early-stage innovations stemming fro...

eyeforpharma Awards 2019
EYEFORPHARMA AWARDS 2019
December 11-11, 2019
You’ll already know if you’re a winner: your patients are telling you. But now it’s time to be recognised by your peers and the wider healthcare community. The eyeforpharma awards are unique. They’re the only awards that focus exclusively on what matters - value for patients ...

Columbia Healthcare

Columbia Healthcare China was founded by Columbia Pacific Management Inc.(CPM). With headquarter is in Seattle, USA, CPM is an international business that develops and operates hospitals, clinics and senior living facilities. CPM has nearly 30 hospitals, clinics, and extended care facilities in Malaysia, India, Vietnam and Indonesia. In Year 2011, Columbia China set up the head office in Shanghai. To meet China's growing demand for international standard medical services, Columbia China will invest in the establishment of a number of comprehensive, specialized hospitals, clinics, pension care and rehabilitation facilities throughout the country.

RELATED NEWS


The US Food and Drug Administration (FDA) cleared Glenmark Pharmaceutical’s investigational new drug (IND) application to initiate a phase I study of its lead candidate, GBR 1302-BEAT, in patients with HER2+ cancers....

READ MORE

AstraZeneca already has a Tagrisso approval for patients with previously untreated, EGFR-mutated lung cancer. But its shoring up its case with some clutch new data. Friday, the British drugmaker said Tagrisso had beaten out Roches rival drug Tarceva and AstraZenecas own Iressa at helping patients live longer. The showing came as part of the phase 3 Flaura trial the same study that helped net Tagrisso its approval last year based on a reduction in the risk of disease progression. That overall sur...
FIERCE PHARMA
READ MORE

Plantronics, Inc. (“Poly” – formerly Plantronics and Polycom) (NYSE: PLT), a global communications company that powers meaningful human connection and collaboration, will introduce video conferencing devices with a built-in Microsoft Teams experience at Microsoft Ignite 2019. The Poly Studio X Series, purpose-built, all-in-one video bars for Microsoft teams, will offer a native Teams meeting and calling experience and are among a host of Poly solutions built for Teams that the ...
SOURCE
READ MORE

Roche’s Tecentriq was the third PD-1/PD-L1 inhibitor to reach the market but is the first in class to be approved for any form of breast cancer. PD-L1 inhibitor Tecentriq (atezolizumab) has been cleared by the FDA for advanced triple-negative breast cancer (TNBC), in combination with Celgene’s chemotherapy drug Abraxane (nab-paclitaxel), in patients with locally advanced or metastatic PD-L1-positive tumors. The green light comes after a six-month priority review by the FDSA and is a ...

READ MORE

Biotech and pharma companies came roaring out of the gate on the first day of the annual J.P. Morgan Healthcare Conference with big deals, expansions, and promises of growth and pipeline sustainability. First out of the gate was Eli Lilly’s $8 billion acquisition of Loxo Oncology. The deal deepened Eli Lilly’s commitment to its oncology pipeline with the recently-approved Vitrakvi (larotrectinib), an oral TRK inhibitor. The deal also provided Lilly with several other pipeline candida...

READ MORE

US regulators have accepted for review Eli Lilly’s investigational non-opioid pain drug galcanezumab for the prevention of a migraine. The drug - a monoclonal antibody designed to bind to and inhibit the activity of calcitonin gene-related peptide (CGRP), which is believed to play a role in a migraine and cluster headache - has been submitted for use as a once-monthly, self-administered injection via auto-injector pen or prefilled syringe. The move rides on the back data from three Phase I...

READ MORE

EVENTS

BIOFIT 2019
BIOFIT 2019
December 10-11, 2019
With the highest attending rate of academics, TTOs and research institutions, BioFIT is the place where academia-industry collaborations get started. BioFIT has taken on a whole new dimension becoming the meeting point in Europe for tech transfer and for sourcing early-stage innovations stemming fro...

SiriusDecisions 2019 Technology Exchange
SIRIUSDECISIONS 2019 TECHNOLOGY EXCHANGE
December 09-11, 2019
The drive for growth never ceases for b-to-b organizations, and more than ever technology is at the centre of enabling that progress. Gone are the days however when a disparate, disconnected set of platforms strewn across sales, marketing an product can serve the organization effectively. An aligned...